By going deeper into recent drug discovery programs, we exemplify how to de-risk your drug discovery programs and overcome the obstacles you may encounter when developing a novel preclinical compound: how to identify novel small molecule inhibitors by a phenotypic screening approach, how to deconvolute the underlying target, how to gain a deeper understanding of the Mode of Action and to assess the therapeutic potential and the PK/PD relationship of novel compounds in vivo.
